Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Recruiting · NCT06458036 · Registry updated 2026-07-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE) | Head and Neck Neoplasms, Neoplasms by Site, cancer, childhood malignant neoplasm, differentiated thyroid carcinoma, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor | Recruiting | Phase 2 | 2026-07-24 | NCT06458036 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Children's Hospital of Philadelphia | 215 |
| Eli Lilly and Company | 370 |
| United States Department of Defense | 319 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | United States | 434 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Seattle Children's Hospital | Seattle | United States | 281 |
| St. Jude Children's Research Hospital | Memphis | United States | 194 |
| The Unviersity of California, San Francisco (UCSF) | San Francisco | United States | 1 |